In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 36191321.
- Also identified by DOI 10.7326/J22-0077.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. <b>Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.</b> Lancet Neurol. 2022;21:597-607. 35716692.
Medical subject headings
- Migraine Disorders